Is SBRA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Senior housing operating recovery, with revenue (ttm) at ~$864M (+25% y/y in Q2 2026). The bear case rests on sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. Analysts covering it are spread from $19.00 to $25.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $19.00, -1.8% from the $19.34 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Senior housing operating recovery. Sabra's managed senior housing portfolio is the main growth engine, with same-store cash NOI up 13.7% year over year in the second quarter of 2026 (after roughly 14% in the first), occupancy up 170 basis points to 88.2%, and revenue per occupied unit up 6.6%. The most optimistic analyst target on SBRA is $25.00, +29.3% from the $19.34 price. That figure is only reachable if this thesis works close to its best case.

Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The re-tenanting of properties (such as the Avamere-to-Cascadia transition) carries execution risk during handover. As a REIT it is sensitive to interest rates, which affect both its borrowing costs and how income investors value its yield. Leverage remains meaningful for a healthcare landlord, and the dividend, while covered by cash flow today, depends on continued occupancy recovery. Competition from far larger peers for acquisitions can compress the yields Sabra earns on new deals. The second-quarter 2026 provision of $102.4 million for loan losses, tied to the discounted payoff of a mortgage loan, is a reminder that Sabra's lending and leasing exposure to operators can produce sizable write-downs. Reliance on forward equity sales to fund acquisitions also dilutes existing holders, and GAAP payout ratios look stretched (the trailing dividend is several times GAAP earnings) even though the normalized AFFO payout is about 75%. The most pessimistic published target is $19.00, -1.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, mana

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Senior housing operating recovery) stalling in the reported numbers rather than in the narrative, the risk above (sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Sabra owns and invests in healthcare real estate across the US and Canada, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals. It earns money from rent on leased properties and from operating income on its managed senior housing assets.

Yes. Sabra pays a quarterly cash dividend of $0.30 per share, or $1.20 annually, which works out to a yield of about 6.2% at the October 16, 2026 price of $19.41. In the second quarter of 2026 the payout was about 75% of normalized AFFO, leaving some coverage cushion.

It behaves mainly as an income stock. Investors generally hold it for the roughly 6.2% dividend yield, with modest per-share FFO growth (the 2026 guidance midpoint implies about 7% normalized FFO and 8% normalized AFFO growth) layered on top from senior housing recovery and acquisitions rather than rapid expansion.